Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01910012 · ClinicalTrials.gov registry record · Phase 2
PH 2 ADI-PEG 20 Acute Myeloid Leukemia
A Phase 2 study, sponsored by Polaris Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT01910012 is a Phase 2 study that has completed, run by Polaris Group. The registered enrollment target is 43 participants.
The verdict
NCT01910012, a Phase 2 study, has completed, sponsored by Polaris Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers that require arginine. In this study, the investigators will evaluate the response rate, as determined by the revised International Working Group recommendations.
Interventions
- DRUG ADI-PEG 20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2015-01-06 |
| Est. Completion | 2017-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01910012
The ClinicalTrials.gov registry entry for NCT01910012 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Polaris Group, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADI-PEG 20 is the first listed.
NCT01910012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01910012 about?
NCT01910012 is a clinical study titled "PH 2 ADI-PEG 20 Acute Myeloid Leukemia". Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers that require arginine. In this study, the investigators will evaluate the...
What is the current status of trial NCT01910012?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2015-01-06. Estimated completion is 2017-05-05.
What interventions are being tested in trial NCT01910012?
The interventions under investigation include: ADI-PEG 20 (DRUG).
Who is sponsoring clinical trial NCT01910012?
This trial is sponsored by Polaris Group, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.